These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 29052780)

  • 1. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?
    Obeid JM; Kunk PR; Zaydfudim VM; Bullock TN; Slingluff CL; Rahma OE
    Cancer Immunol Immunother; 2018 Feb; 67(2):161-174. PubMed ID: 29052780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
    Keenan BP; Fong L; Kelley RK
    J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions.
    Zhu J; Yin T; Xu Y; Lu XJ
    J Cell Physiol; 2019 Aug; 234(8):12122-12132. PubMed ID: 30644100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.
    Hato T; Goyal L; Greten TF; Duda DG; Zhu AX
    Hepatology; 2014 Nov; 60(5):1776-82. PubMed ID: 24912948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma: systemic therapies and future perspectives.
    Mikhail S; Cosgrove D; Zeidan A
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1205-18. PubMed ID: 25199765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.
    Wang L; Wang FS
    Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic advances for patients with intermediate hepatocellular carcinoma.
    Sun JY; Yin T; Zhang XY; Lu XJ
    J Cell Physiol; 2019 Aug; 234(8):12116-12121. PubMed ID: 30648254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological landscape and immunotherapy of hepatocellular carcinoma.
    Prieto J; Melero I; Sangro B
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
    Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
    World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies.
    Bertino G; Demma S; Ardiri A; Proiti M; Mangia A; Gruttadauria S; Toro A; Di Carlo I; Malaguarnera G; Bertino N; Malaguarnera M; Malaguarnera M
    Biomed Res Int; 2015; 2015():731469. PubMed ID: 25893197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches.
    Lindemann J; Yu J; Doyle MBM
    Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma in the era of immunotherapy.
    Sim HW; Knox J
    Curr Probl Cancer; 2018; 42(1):40-48. PubMed ID: 29150141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.